Opinion|Videos|March 17, 2025
CAR T in the Real World: Clinician Perspectives on Outcomes, Toxicity, and Patient Management
Panelists discuss the comparison between clinical trial results and real-world outcomes for chimeric antigen receptor T-cell (CAR T) therapies like liso-cel and axi-cel. Clinical trials have shown promising efficacy and manageable safety profiles for both therapies in treating certain blood cancers. However, real-world evidence continues to emerge through ongoing clinical use and registry data collection.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How do the efficacy and safety outcomes of liso-cel and axi-cel in clinical trials compare to what you have observed in real-world practice?
- Are there specific patient populations or clinical scenarios where you find the trial data align—or diverge—from real-world experiences with CAR T therapy?
Advertisement
Related to this article
Data from the phase 3 MANGROVE study support the application for zanubrutinib/rituximab in this mantle cell lymphoma population.
In the phase 2 DALY 2-EU trial, zamto-cel prolonged median event-free survival vs R-GemOx in transplant-ineligible relapsed/refractory large B-cell lymphoma.
Rocbrutinib plus R-CHOP yielded a 100% ORR and an 86.7% CR rate in 15 patients with untreated non-GCB DLBCL, warranting randomized evaluation.
Grade 3/4 neurotoxicity in patients prompted a partial clinical hold on the PALISADES-1 and PALISADES-2 trials of KITE-753 in large B-cell lymphoma.
In a phase 2 trial, orelabrutinib plus sintilimab yielded a 60.7% overall response rate in relapsed/refractory primary CNS lymphoma.
Advertisement
Advertisement
Trending on CancerNetwork
1
MASLD Raises Liver and Other Cancer Risks, Supporting Selective HCC Surveillance
2
Weighing Immunotherapy for Bridging and Downstaging Before HCC Transplant
3
What Separates a Next-Generation Liver Tumor Board From the Traditional Model?
4
BOT+BAL Yields Long-Term Survival in Patients With Refractory MSS mCRC
5